liver cancer cells Search Results


93
ATCC liver cancer cell lines
Liver Cancer Cell Lines, supplied by ATCC, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/liver cancer cell lines/product/ATCC
Average 93 stars, based on 1 article reviews
liver cancer cell lines - by Bioz Stars, 2026-03
93/100 stars
  Buy from Supplier

92
Celprogen Inc liver cancer stem cells lcscs
Levels of AKT signaling molecules (phosphorylated AKT and phosphorylated mTORC1) in <t>normal</t> <t>hepatocytes</t> and <t>LCSCs</t> under various exosomes. (CE: control cellular exosome, UPE: upregulated PRELI cellular exosome, DPEs: downregulated PRELI cellular exosome) (* p < 0.05, ** p < 0.01,*** p < 0.001).
Liver Cancer Stem Cells Lcscs, supplied by Celprogen Inc, used in various techniques. Bioz Stars score: 92/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/liver cancer stem cells lcscs/product/Celprogen Inc
Average 92 stars, based on 1 article reviews
liver cancer stem cells lcscs - by Bioz Stars, 2026-03
92/100 stars
  Buy from Supplier

90
Celprogen Inc human liver cancer cell line
Levels of AKT signaling molecules (phosphorylated AKT and phosphorylated mTORC1) in <t>normal</t> <t>hepatocytes</t> and <t>LCSCs</t> under various exosomes. (CE: control cellular exosome, UPE: upregulated PRELI cellular exosome, DPEs: downregulated PRELI cellular exosome) (* p < 0.05, ** p < 0.01,*** p < 0.001).
Human Liver Cancer Cell Line, supplied by Celprogen Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/human liver cancer cell line/product/Celprogen Inc
Average 90 stars, based on 1 article reviews
human liver cancer cell line - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier

90
Johns Hopkins HealthCare liver cancer cell line hep3b
Levels of AKT signaling molecules (phosphorylated AKT and phosphorylated mTORC1) in <t>normal</t> <t>hepatocytes</t> and <t>LCSCs</t> under various exosomes. (CE: control cellular exosome, UPE: upregulated PRELI cellular exosome, DPEs: downregulated PRELI cellular exosome) (* p < 0.05, ** p < 0.01,*** p < 0.001).
Liver Cancer Cell Line Hep3b, supplied by Johns Hopkins HealthCare, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/liver cancer cell line hep3b/product/Johns Hopkins HealthCare
Average 90 stars, based on 1 article reviews
liver cancer cell line hep3b - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier

90
iCell Bioscience Inc mouse liver cancer cell lines h22
CD3+CD8+ T cell-mediated cytotoxicity was measured by flow cytometry. A. For <t>H22</t> cells, the cytotoxicity in the LV-SMP30 group at the ratio of 10:1, 20:1 or 40:1. B. Statistical chart of target cell H22 specific lysis (%) in each group under different effector-target ratios. C. For Hep1-6 cells, the cytotoxicity in LV-SMP30 group at the ratio of 10:1, 20:1 or 40:1. D. Statistical chart of target cell Hep1-6 specific lysis (%) in each group under different effector-target ratios. These results indicate that LV-SMP30 transduced DCs enhances the CD3+CD8+ T cell-mediated specific cytotoxicity against H22 cells.
Mouse Liver Cancer Cell Lines H22, supplied by iCell Bioscience Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/mouse liver cancer cell lines h22/product/iCell Bioscience Inc
Average 90 stars, based on 1 article reviews
mouse liver cancer cell lines h22 - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier

90
Procell Inc human liver cancer cell line 7,721
CD3+CD8+ T cell-mediated cytotoxicity was measured by flow cytometry. A. For <t>H22</t> cells, the cytotoxicity in the LV-SMP30 group at the ratio of 10:1, 20:1 or 40:1. B. Statistical chart of target cell H22 specific lysis (%) in each group under different effector-target ratios. C. For Hep1-6 cells, the cytotoxicity in LV-SMP30 group at the ratio of 10:1, 20:1 or 40:1. D. Statistical chart of target cell Hep1-6 specific lysis (%) in each group under different effector-target ratios. These results indicate that LV-SMP30 transduced DCs enhances the CD3+CD8+ T cell-mediated specific cytotoxicity against H22 cells.
Human Liver Cancer Cell Line 7,721, supplied by Procell Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/human liver cancer cell line 7,721/product/Procell Inc
Average 90 stars, based on 1 article reviews
human liver cancer cell line 7,721 - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier

90
Broad Institute Inc rna-seq data of different human liver cancer cell lines
CD3+CD8+ T cell-mediated cytotoxicity was measured by flow cytometry. A. For <t>H22</t> cells, the cytotoxicity in the LV-SMP30 group at the ratio of 10:1, 20:1 or 40:1. B. Statistical chart of target cell H22 specific lysis (%) in each group under different effector-target ratios. C. For Hep1-6 cells, the cytotoxicity in LV-SMP30 group at the ratio of 10:1, 20:1 or 40:1. D. Statistical chart of target cell Hep1-6 specific lysis (%) in each group under different effector-target ratios. These results indicate that LV-SMP30 transduced DCs enhances the CD3+CD8+ T cell-mediated specific cytotoxicity against H22 cells.
Rna Seq Data Of Different Human Liver Cancer Cell Lines, supplied by Broad Institute Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/rna-seq data of different human liver cancer cell lines/product/Broad Institute Inc
Average 90 stars, based on 1 article reviews
rna-seq data of different human liver cancer cell lines - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier

90
CH Instruments ec4 mouse liver cancer cell line
(A) Bar graph representation of the fold change in IC50 with RA-drug combination. Combination of 5-fluorouracil shows negligible change in IC50, and oxaliplatin-RA showed a 1.6-fold change in IC50, signifying some synergy. However, combination of RA and Paclitaxel had a 2.5-fold reduced IC50 than parent chemotherapeutic (Paclitaxel), signifying maximum synergy among the three combinations and the best candidates for further experiments. (B) Molar ratio dictates improvement in IC50 with combination of TAX and RA, with 1:100 being optimal. (C) Testing of RA, TAX, and RA-TAX loaded filomicelles on <t>EC4</t> mouse liver cancer cells. TAX (black) has a much lower IC50 than RA (red) as it induces apoptosis instead of arresting proliferation. However, the combination of RA-TAX is more effective than either drug alone, with its IC50 less than half of that for TAX. Empty filomicelles (blue curve) were inert at the desired concentrations. (D) Nuclei treated with Paclitaxel (TAX) exhibit massive blebbed nuclei due to incomplete division (bottom). Untreated nuclei (top) in contrast are smooth and rounded. (E) Schematic depicting culture of resistant colonies arising after RA-TAX filomicelle treatment. (F) Plotting the proliferation rate against the degree of resistance gives an inverse relation, supporting the hypothesis that acquisition of drug-resistance occurs at the cost of proliferation.
Ec4 Mouse Liver Cancer Cell Line, supplied by CH Instruments, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/ec4 mouse liver cancer cell line/product/CH Instruments
Average 90 stars, based on 1 article reviews
ec4 mouse liver cancer cell line - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier

90
GenScript corporation h22 mouse liver cancer cell specific neoantigen (sequence: htdahaqafaalfdsmh)
Schematic illustration of remodeling tumor‐associated neutrophils to enhance DC‐based HCC <t>neoantigen</t> nano‐vaccine efficiency. The H22 liver cancer cell‐specific neoantigens are predicted by in silico analysis and confirmed through ELISPOT. Afterward, the neoantigen activated DC‐based nano‐vaccines are prepared, which can not only actively target H22 tumor tissues to enhance TAA release through PDT but achieved the lymph‐homing ability to directly induce the activation and proliferation of CD8+T cells. These led to strengthening the immune responses against the primary and distant tumor growth. More strikingly, the tumor acidic‐triggered release of captopril can reduce the protumoral N2 phenotype to further improve the immune effects to further augment the suppression of both the primary and distance tumor growth, therefore prolonging the survival of H22‐bearing mice.
H22 Mouse Liver Cancer Cell Specific Neoantigen (Sequence: Htdahaqafaalfdsmh), supplied by GenScript corporation, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/h22 mouse liver cancer cell specific neoantigen (sequence: htdahaqafaalfdsmh)/product/GenScript corporation
Average 90 stars, based on 1 article reviews
h22 mouse liver cancer cell specific neoantigen (sequence: htdahaqafaalfdsmh) - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier

90
Korean Cell Line Bank liver cancer cell lines
Schematic illustration of remodeling tumor‐associated neutrophils to enhance DC‐based HCC <t>neoantigen</t> nano‐vaccine efficiency. The H22 liver cancer cell‐specific neoantigens are predicted by in silico analysis and confirmed through ELISPOT. Afterward, the neoantigen activated DC‐based nano‐vaccines are prepared, which can not only actively target H22 tumor tissues to enhance TAA release through PDT but achieved the lymph‐homing ability to directly induce the activation and proliferation of CD8+T cells. These led to strengthening the immune responses against the primary and distant tumor growth. More strikingly, the tumor acidic‐triggered release of captopril can reduce the protumoral N2 phenotype to further improve the immune effects to further augment the suppression of both the primary and distance tumor growth, therefore prolonging the survival of H22‐bearing mice.
Liver Cancer Cell Lines, supplied by Korean Cell Line Bank, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/liver cancer cell lines/product/Korean Cell Line Bank
Average 90 stars, based on 1 article reviews
liver cancer cell lines - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier

90
Cold Spring Harbor Laboratory Meetings liver-cancer cell lines
Schematic illustration of remodeling tumor‐associated neutrophils to enhance DC‐based HCC <t>neoantigen</t> nano‐vaccine efficiency. The H22 liver cancer cell‐specific neoantigens are predicted by in silico analysis and confirmed through ELISPOT. Afterward, the neoantigen activated DC‐based nano‐vaccines are prepared, which can not only actively target H22 tumor tissues to enhance TAA release through PDT but achieved the lymph‐homing ability to directly induce the activation and proliferation of CD8+T cells. These led to strengthening the immune responses against the primary and distant tumor growth. More strikingly, the tumor acidic‐triggered release of captopril can reduce the protumoral N2 phenotype to further improve the immune effects to further augment the suppression of both the primary and distance tumor growth, therefore prolonging the survival of H22‐bearing mice.
Liver Cancer Cell Lines, supplied by Cold Spring Harbor Laboratory Meetings, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/liver-cancer cell lines/product/Cold Spring Harbor Laboratory Meetings
Average 90 stars, based on 1 article reviews
liver-cancer cell lines - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier

90
Korean Cell Line Bank human liver cancer cell lines huh-7 (mutant tp53)
Schematic illustration of remodeling tumor‐associated neutrophils to enhance DC‐based HCC <t>neoantigen</t> nano‐vaccine efficiency. The H22 liver cancer cell‐specific neoantigens are predicted by in silico analysis and confirmed through ELISPOT. Afterward, the neoantigen activated DC‐based nano‐vaccines are prepared, which can not only actively target H22 tumor tissues to enhance TAA release through PDT but achieved the lymph‐homing ability to directly induce the activation and proliferation of CD8+T cells. These led to strengthening the immune responses against the primary and distant tumor growth. More strikingly, the tumor acidic‐triggered release of captopril can reduce the protumoral N2 phenotype to further improve the immune effects to further augment the suppression of both the primary and distance tumor growth, therefore prolonging the survival of H22‐bearing mice.
Human Liver Cancer Cell Lines Huh 7 (Mutant Tp53), supplied by Korean Cell Line Bank, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/human liver cancer cell lines huh-7 (mutant tp53)/product/Korean Cell Line Bank
Average 90 stars, based on 1 article reviews
human liver cancer cell lines huh-7 (mutant tp53) - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier

Image Search Results


Levels of AKT signaling molecules (phosphorylated AKT and phosphorylated mTORC1) in normal hepatocytes and LCSCs under various exosomes. (CE: control cellular exosome, UPE: upregulated PRELI cellular exosome, DPEs: downregulated PRELI cellular exosome) (* p < 0.05, ** p < 0.01,*** p < 0.001).

Journal: International Journal of Molecular Sciences

Article Title: MicroRNA Profiling of PRELI-Modulated Exosomes and Effects on Hepatic Cancer Stem Cells

doi: 10.3390/ijms252413299

Figure Lengend Snippet: Levels of AKT signaling molecules (phosphorylated AKT and phosphorylated mTORC1) in normal hepatocytes and LCSCs under various exosomes. (CE: control cellular exosome, UPE: upregulated PRELI cellular exosome, DPEs: downregulated PRELI cellular exosome) (* p < 0.05, ** p < 0.01,*** p < 0.001).

Article Snippet: Liver cancer stem cells (LCSCs) (sku: 36116-43; Celprogen, Torrance, CA, USA) and normal hepatocytes (NHs) (THLE-3; ATCC, Manassas, VA, USA) were cultured with Human Liver Cancer Stem Cell Media (Celprogen) and BEGM (Bronchial Epithelial Cell Growth Medium) (Lonza, Workingham, UK) using BEGM Bullet Kits (Lonza) at 37 °C, 5% CO 2 .

Techniques: Control

CD3+CD8+ T cell-mediated cytotoxicity was measured by flow cytometry. A. For H22 cells, the cytotoxicity in the LV-SMP30 group at the ratio of 10:1, 20:1 or 40:1. B. Statistical chart of target cell H22 specific lysis (%) in each group under different effector-target ratios. C. For Hep1-6 cells, the cytotoxicity in LV-SMP30 group at the ratio of 10:1, 20:1 or 40:1. D. Statistical chart of target cell Hep1-6 specific lysis (%) in each group under different effector-target ratios. These results indicate that LV-SMP30 transduced DCs enhances the CD3+CD8+ T cell-mediated specific cytotoxicity against H22 cells.

Journal: American Journal of Translational Research

Article Title: Dendritic cells modified by tumor associated antigen SMP30 have enhanced antitumor effect against mouse hepatocarcinoma cells in vitro and in vivo

doi:

Figure Lengend Snippet: CD3+CD8+ T cell-mediated cytotoxicity was measured by flow cytometry. A. For H22 cells, the cytotoxicity in the LV-SMP30 group at the ratio of 10:1, 20:1 or 40:1. B. Statistical chart of target cell H22 specific lysis (%) in each group under different effector-target ratios. C. For Hep1-6 cells, the cytotoxicity in LV-SMP30 group at the ratio of 10:1, 20:1 or 40:1. D. Statistical chart of target cell Hep1-6 specific lysis (%) in each group under different effector-target ratios. These results indicate that LV-SMP30 transduced DCs enhances the CD3+CD8+ T cell-mediated specific cytotoxicity against H22 cells.

Article Snippet: Mouse liver cancer cell lines H22 and Hep1-6 were employed, purchased from iCell Bioscience Inc.

Techniques: Flow Cytometry, Lysis

Construction of BALB/c nude mouse models of subcutaneous xenografts. A. BALB/c nude mice with equal-sized (~100 mm3) single H22 tumors were treated with CD3+CD8+ T cells. B. Recording chart of tumor growth process. C. Tumor volume on day 15: PBS group, Untreated group, LV group, Protein group, LV-SMP30 group (from left to right). D. Tumors harvested from mice on day 15: PBS group, Untreated group, LV group, Protein group, LV-SMP30 group (from left to right). E. Tumor growth curve. These results demonstrated that the tumor volume in the LV-SMP30 group was smaller than that of other control groups (P<0.05).

Journal: American Journal of Translational Research

Article Title: Dendritic cells modified by tumor associated antigen SMP30 have enhanced antitumor effect against mouse hepatocarcinoma cells in vitro and in vivo

doi:

Figure Lengend Snippet: Construction of BALB/c nude mouse models of subcutaneous xenografts. A. BALB/c nude mice with equal-sized (~100 mm3) single H22 tumors were treated with CD3+CD8+ T cells. B. Recording chart of tumor growth process. C. Tumor volume on day 15: PBS group, Untreated group, LV group, Protein group, LV-SMP30 group (from left to right). D. Tumors harvested from mice on day 15: PBS group, Untreated group, LV group, Protein group, LV-SMP30 group (from left to right). E. Tumor growth curve. These results demonstrated that the tumor volume in the LV-SMP30 group was smaller than that of other control groups (P<0.05).

Article Snippet: Mouse liver cancer cell lines H22 and Hep1-6 were employed, purchased from iCell Bioscience Inc.

Techniques: Control

(A) Bar graph representation of the fold change in IC50 with RA-drug combination. Combination of 5-fluorouracil shows negligible change in IC50, and oxaliplatin-RA showed a 1.6-fold change in IC50, signifying some synergy. However, combination of RA and Paclitaxel had a 2.5-fold reduced IC50 than parent chemotherapeutic (Paclitaxel), signifying maximum synergy among the three combinations and the best candidates for further experiments. (B) Molar ratio dictates improvement in IC50 with combination of TAX and RA, with 1:100 being optimal. (C) Testing of RA, TAX, and RA-TAX loaded filomicelles on EC4 mouse liver cancer cells. TAX (black) has a much lower IC50 than RA (red) as it induces apoptosis instead of arresting proliferation. However, the combination of RA-TAX is more effective than either drug alone, with its IC50 less than half of that for TAX. Empty filomicelles (blue curve) were inert at the desired concentrations. (D) Nuclei treated with Paclitaxel (TAX) exhibit massive blebbed nuclei due to incomplete division (bottom). Untreated nuclei (top) in contrast are smooth and rounded. (E) Schematic depicting culture of resistant colonies arising after RA-TAX filomicelle treatment. (F) Plotting the proliferation rate against the degree of resistance gives an inverse relation, supporting the hypothesis that acquisition of drug-resistance occurs at the cost of proliferation.

Journal: Bioconjugate chemistry

Article Title: Filomicelles Deliver a Chemo-Differentiation Combination of Paclitaxel and Retinoic Acid That Durably Represses Carcinomas in Liver to Prolong Survival

doi: 10.1021/acs.bioconjchem.7b00816

Figure Lengend Snippet: (A) Bar graph representation of the fold change in IC50 with RA-drug combination. Combination of 5-fluorouracil shows negligible change in IC50, and oxaliplatin-RA showed a 1.6-fold change in IC50, signifying some synergy. However, combination of RA and Paclitaxel had a 2.5-fold reduced IC50 than parent chemotherapeutic (Paclitaxel), signifying maximum synergy among the three combinations and the best candidates for further experiments. (B) Molar ratio dictates improvement in IC50 with combination of TAX and RA, with 1:100 being optimal. (C) Testing of RA, TAX, and RA-TAX loaded filomicelles on EC4 mouse liver cancer cells. TAX (black) has a much lower IC50 than RA (red) as it induces apoptosis instead of arresting proliferation. However, the combination of RA-TAX is more effective than either drug alone, with its IC50 less than half of that for TAX. Empty filomicelles (blue curve) were inert at the desired concentrations. (D) Nuclei treated with Paclitaxel (TAX) exhibit massive blebbed nuclei due to incomplete division (bottom). Untreated nuclei (top) in contrast are smooth and rounded. (E) Schematic depicting culture of resistant colonies arising after RA-TAX filomicelle treatment. (F) Plotting the proliferation rate against the degree of resistance gives an inverse relation, supporting the hypothesis that acquisition of drug-resistance occurs at the cost of proliferation.

Article Snippet: Primary EC4 mouse liver cancer cell line (c-myc mutation) was acquired from Chi Van Dang’s lab at the University of Pennsylvania and cultured with DMEM High glucose growth media (4.5 g/L glucose with L-glutamine and sodium pyruvate) supplemented with 10% FBS, 1% penicillin− streptomycin, and 1% nonessential amino acids at 37 °C and 5% CO 2 .

Techniques:

Schematic illustration of remodeling tumor‐associated neutrophils to enhance DC‐based HCC neoantigen nano‐vaccine efficiency. The H22 liver cancer cell‐specific neoantigens are predicted by in silico analysis and confirmed through ELISPOT. Afterward, the neoantigen activated DC‐based nano‐vaccines are prepared, which can not only actively target H22 tumor tissues to enhance TAA release through PDT but achieved the lymph‐homing ability to directly induce the activation and proliferation of CD8+T cells. These led to strengthening the immune responses against the primary and distant tumor growth. More strikingly, the tumor acidic‐triggered release of captopril can reduce the protumoral N2 phenotype to further improve the immune effects to further augment the suppression of both the primary and distance tumor growth, therefore prolonging the survival of H22‐bearing mice.

Journal: Advanced Science

Article Title: Remodeling Tumor‐Associated Neutrophils to Enhance Dendritic Cell‐Based HCC Neoantigen Nano‐Vaccine Efficiency

doi: 10.1002/advs.202105631

Figure Lengend Snippet: Schematic illustration of remodeling tumor‐associated neutrophils to enhance DC‐based HCC neoantigen nano‐vaccine efficiency. The H22 liver cancer cell‐specific neoantigens are predicted by in silico analysis and confirmed through ELISPOT. Afterward, the neoantigen activated DC‐based nano‐vaccines are prepared, which can not only actively target H22 tumor tissues to enhance TAA release through PDT but achieved the lymph‐homing ability to directly induce the activation and proliferation of CD8+T cells. These led to strengthening the immune responses against the primary and distant tumor growth. More strikingly, the tumor acidic‐triggered release of captopril can reduce the protumoral N2 phenotype to further improve the immune effects to further augment the suppression of both the primary and distance tumor growth, therefore prolonging the survival of H22‐bearing mice.

Article Snippet: H22 mouse liver cancer cell‐specific neoantigen (sequence: HTDAHAQAFAALFDSMH) was obtained from GenScript USA Inc.

Techniques: Immunopeptidomics, In Silico, Enzyme-linked Immunospot, Vaccines, Activation Assay

Characterization of mD@cSMN nano‐vaccines. A) Schematic illustration of the preparation of mD@cSMN nano‐vaccines. B) TEM image of SMN photosensitizers and the size distribution of SMNs (insert picture). C) The absorbance of DPBF after decomposition by generated 1 O 2 from SMN with and without D) 670 nm laser irradiation (50 mW cm −2 ) for different times. E) The normalized absorbance of DPBF at 415 nm after decomposition by ROS generation in SMNs with or without irradiation for different times and the DPBF without SMN is used as the control. F) The maturation of BMDCs after co‐incubation with PBS or H22 tumor cell‐specific neoantigen for 72 h, respectively, which are analyzed by FACS with staining CD80 and CD86 antibodies. G) The TEM image of mD@cSMN nano‐vaccines and their size distribution (insert picture). H) The surface zeta potential of the SMNs, SMNs‐NH 2 , Fe‐SMNs, cSMNs, the mature DCs membrane, and mD@cSMNs, ( n = 3). I) The protein pattern analysis of matured DCs membrane and mD@cSMNs through SDS‐PAGE (coomassie blue staining). J) Western blotting analysis of membrane‐specific protein markers. The samples are run at equal protein amounts and blotted with CD80, CD86, and MHC‐II antibodies. K) The cumulative captopril release kinetics from mD@cSMNs in different pH conditions within 20 h.

Journal: Advanced Science

Article Title: Remodeling Tumor‐Associated Neutrophils to Enhance Dendritic Cell‐Based HCC Neoantigen Nano‐Vaccine Efficiency

doi: 10.1002/advs.202105631

Figure Lengend Snippet: Characterization of mD@cSMN nano‐vaccines. A) Schematic illustration of the preparation of mD@cSMN nano‐vaccines. B) TEM image of SMN photosensitizers and the size distribution of SMNs (insert picture). C) The absorbance of DPBF after decomposition by generated 1 O 2 from SMN with and without D) 670 nm laser irradiation (50 mW cm −2 ) for different times. E) The normalized absorbance of DPBF at 415 nm after decomposition by ROS generation in SMNs with or without irradiation for different times and the DPBF without SMN is used as the control. F) The maturation of BMDCs after co‐incubation with PBS or H22 tumor cell‐specific neoantigen for 72 h, respectively, which are analyzed by FACS with staining CD80 and CD86 antibodies. G) The TEM image of mD@cSMN nano‐vaccines and their size distribution (insert picture). H) The surface zeta potential of the SMNs, SMNs‐NH 2 , Fe‐SMNs, cSMNs, the mature DCs membrane, and mD@cSMNs, ( n = 3). I) The protein pattern analysis of matured DCs membrane and mD@cSMNs through SDS‐PAGE (coomassie blue staining). J) Western blotting analysis of membrane‐specific protein markers. The samples are run at equal protein amounts and blotted with CD80, CD86, and MHC‐II antibodies. K) The cumulative captopril release kinetics from mD@cSMNs in different pH conditions within 20 h.

Article Snippet: H22 mouse liver cancer cell‐specific neoantigen (sequence: HTDAHAQAFAALFDSMH) was obtained from GenScript USA Inc.

Techniques: Vaccines, Generated, Irradiation, Control, Incubation, Staining, Zeta Potential Analyzer, Membrane, SDS Page, Western Blot